<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195971</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2019-2587</org_study_id>
    <nct_id>NCT04195971</nct_id>
  </id_info>
  <brief_title>Dual Arterial Phase Liver CT in Patients With Suspected Portal Hypertension</brief_title>
  <official_title>Multiphasic Liver CT Scan Including Dual Arterial Phase Imaging in Patients With Liver Cirrhosis and Suspected Portal Hypertension: Evaluation of Acquisition of Appropriate Late Arterial Phase Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with liver cirrhosis is at risk of developing HCC. To diagnose or detect HCC at
      CT/MRI, optimal late arterial phase (LAP) acquisition is critical to capture the tumor. For
      LAP acquisition, bolus-tracking is often used at CT. In patients with portal hypertension,
      however, bolus-tracking occasionally capture early arterial phase which may be related with
      slow portomesenteric flow. In this study, we obtain dual arterial phase in patients with
      suspected portal hypertension and determine whether this protocol (dual arterial phase) would
      provide higher incidence of LAP acquisition than single arterial phase acquisition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of optimal late arterial phase acquisition</measure>
    <time_frame>1 months after study completion</time_frame>
    <description>incidences of optimal late arterial phase acquisition in 1st and 2nd acquisition of arterial phase in this protocol (dual arterial phase) CT.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>HCC</condition>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Liver CT with dual arterial phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver CT</intervention_name>
    <description>Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.</description>
    <arm_group_label>Liver CT with dual arterial phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 20 years

          -  Liver cirrhosis diagnosed with characteristic imaging feature or histology

          -  Presence of portal hypertension sign (splenomegaly and varices)

          -  Scheduled for liver CT

          -  And signed informed consent

        Exclusion Criteria:

          -  Relative or absolute contra-indication of contrast-enhanced CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Hee Lee, RN</last_name>
    <phone>82-2-2072-4177</phone>
    <email>redlion55@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong Hee Yoon, MD</last_name>
    <phone>82-2-2072-2584</phone>
    <email>jhjhry@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Hee Lee, RN</last_name>
      <phone>82-2-2072-4177</phone>
      <email>redlion55@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeong Hee Yoon, MD</last_name>
      <phone>82-2-2072-2584</phone>
      <email>jhjhry@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeong Min Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

